Compare AZZ & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZZ | STVN |
|---|---|---|
| Founded | 1956 | 1949 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Containers/Packaging |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.7B |
| IPO Year | 1994 | 2021 |
| Metric | AZZ | STVN |
|---|---|---|
| Price | $148.06 | $19.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $141.80 | $25.67 |
| AVG Volume (30 Days) | ★ 306.1K | 304.7K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.58% | 0.39% |
| EPS Growth | ★ 486.59 | N/A |
| EPS | ★ 1.72 | N/A |
| Revenue | ★ $1,061,817,000.00 | N/A |
| Revenue This Year | $7.03 | $9.67 |
| Revenue Next Year | $4.25 | $9.99 |
| P/E Ratio | $88.23 | ★ $27.15 |
| Revenue Growth | ★ 14.53 | N/A |
| 52 Week Low | $92.98 | $12.89 |
| 52 Week High | $162.20 | $28.00 |
| Indicator | AZZ | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 49.80 | 54.53 |
| Support Level | $132.06 | $13.58 |
| Resistance Level | $151.67 | $19.41 |
| Average True Range (ATR) | 5.78 | 0.81 |
| MACD | -0.44 | 0.06 |
| Stochastic Oscillator | 58.65 | 65.46 |
AZZ Inc is a provider of galvanizing and coil coating solutions to a broad range of end markets in North America. The company's operating segment consists of AZZ Metal Coatings, AZZ Precoat Metals, and AZZ Infrastructure Solutions. The company generates the majority of its revenue from the Precoat Metals segment, which provides coil coating application of protective and decorative coatings and related value-added downstream processing for steel and aluminum coils. Geographically, the company operates in the United States and Canada.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.